Evidence map›Paper›PMID 33063013›Full record

ArticleNeuro-oncology advances

Increased epithelial membrane protein 2 expression in glioblastoma after treatment with bevacizumab.

Kunal S Patel, Sameer Kejriwal, Samasuk Thammachantha, Courtney Duong, Adrian Murillo, Lynn K Gordon, Timothy F Cloughesy, Linda Liau, William Yong, Isaac Yang and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Kunal S PatelDepartment of Neurosurgery, University of California Los Angeles, Los Angeles, California, USA.ORCID 0000-0002-9854-9178
Sameer KejriwalDepartment of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, California, USA.
Samasuk ThammachanthaDepartment of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, California, USA.
Courtney DuongDepartment of Neurosurgery, University of California Los Angeles, Los Angeles, California, USA.
Adrian MurilloDepartment of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, California, USA.
Lynn K GordonDepartment of Ophthalmology, University of California Los Angeles, Los Angeles, California, USA.
Timothy F CloughesyDepartment of Neurosurgery, University of California Los Angeles, Los Angeles, California, USA.
Linda LiauDepartment of Neurosurgery, University of California Los Angeles, Los Angeles, California, USA.
William YongDepartment of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, California, USA.
Isaac YangDepartment of Neurosurgery, University of California Los Angeles, Los Angeles, California, USA.
Madhuri WadehraDepartment of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, California, USA.
University of California, Los Angeles · US

Funding

UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI David A. Nathanson · 2017 to 2026
$25.2M
UCLA IDDRC: Translational CoreP50HD103557 · NICHD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Peyman Golshani, SUMA JACOB · 2020 to 2026
$9.6M
Using EMP2 for Image Guided Drug Delivery for Breast CancerR01CA163971 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI OLAFSEN, TOVE, WADEHRA, MADHURI · 2012 to 2016
$1.6M
NCI NIH HHS P50 CA211015NCI NIH HHS R01 CA163971NICHD NIH HHS P50 HD103557
6 · The paper itself

Abstract

backgroundAntiangiogenic therapy with bevacizumab has failed to provide substantial gains in overall survival. Epithelial membrane protein 2 (EMP2) is a cell surface protein that has been previously shown to be expressed in glioblastoma, correlate with poor survival, and regulate neoangiogenesis in cell lines. Thus, the relationship between bevacizumab and EMP2 was investigated.

methodsTumor samples were obtained from 12 patients with newly diagnosed glioblastoma at 2 time points: (1) during the initial surgery and (2) during a subsequent surgery following disease recurrence post-bevacizumab treatment. Clinical characteristics and survival data from these patients were collected, and tumor samples were stained for EMP2 expression. The IVY Glioblastoma Atlas Project database was used to evaluate EMP2 expression levels in 270 samples by differing histological areas of the tumor.

resultsPatients with high EMP2 staining at initial diagnosis had decreased progression-free and overall survival after bevacizumab (

conclusionsBevacizumab treatment increased EMP2 protein expression. This increase in EMP2 correlated with reduced mean survival time post-bevacizumab therapy. We hypothesize a role of EMP2 in clinical bevacizumab resistance and as a potential antiangiogenic therapeutic target in glioblastoma.

Indexed as

angiogenesisbevacizumabEMP2glioblastoma

Identifiers

PMID33063013
PMCPMC7542982
OpenAlexW3084203535

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.